Prof. Xuan Hong 洪璇
Chief Physician, Professor
Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of thoracic tumors, particularly lung cancer and malignant pleural mesothelioma. Expertise includes chemotherapy, targeted therapy, immunotherapy, and palliative care.
Dr. Hong has worked at Harbin Medical University Cancer Hospital since 2006. From August 2016 to July 2017, Dr. Hong was a visiting scholar at MD Anderson Cancer Center, studying resistance mechanisms in lung cancer targeted therapy. Research focuses on molecular targeted therapy and resistance mechanisms. Dr. Hong has led multiple research projects and published 7 SCI-indexed papers.
Professional roles
- Vice Chair, Youth Committee of the Lung Tumor Professional Committee, China Medicine Education Association
- Youth Member, Nutrition and Supportive Care Committee, China Anti-Cancer Association
- Member, Lung Cancer Group, Biological Therapy Professional Committee, Chinese Research Hospital Association
- Standing Committee Member and Secretary, Lung Cancer Professional Committee, Heilongjiang Anti-Cancer Association
Name order: in Chinese the family name comes first (Hong Xuan). Papers usually list the name as Xuan Hong or Hong X.
Selected publications
15 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Biol Chem, 2023 (first author): Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma. PubMed 37178919
- Int J Clin Pract, 2021 (senior author): Clinical outcomes of patients taking first-generation EGFR-TKIs may predict the benefits afforded by osimertinib in EGFR T790M-mutant NSCLC patients. PubMed 34525256
- Exp Ther Med, 2018 (senior author): miR-6852 serves as a prognostic biomarker in colorectal cancer and inhibits tumor growth and metastasis by targeting TCF7. PubMed 30116340
- Clin Respir J, 2018 (first author): The value of prognostic factors in Chinese patients with small cell lung cancer: A retrospective study of 999 patients. PubMed 27460525
- Tumour Biol, 2016 (first author): Reduced decorin expression in the tumor stroma correlates with tumor proliferation and predicts poor prognosis in patients with I-IIIA non-small cell lung cancer. PubMed 27726099
- Tohoku J Exp Med, 2015 (first author): Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer. PubMed 26250537
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion